文献情報を更新いたしました。

NS-A2

Dual-antigen targeted iPSC-derived chimeric antigen receptor-T cell therapy for refractory lymphoma. Sakiko Harada., et al. Molecular therapy Vol. 30 No 2: 534-549 https://doi.org/10.1016/j.ymthe.2021.10.006

DCO-K

Clinical Trial on the Safety and Tolerability of Personalized Cancer Vaccines Using Human Platelet Lysate-Induced Antigen-Presenting Cells. Terutsugu Koya., et al. Cancers 2023, 15, 3627. https://doi.org/10.3390/cancers15143627